JP2016534084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534084A5 JP2016534084A5 JP2016526034A JP2016526034A JP2016534084A5 JP 2016534084 A5 JP2016534084 A5 JP 2016534084A5 JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016534084 A5 JP2016534084 A5 JP 2016534084A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- compound
- group
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 4
- 101150025421 ETS gene Proteins 0.000 claims 3
- 102100039563 ETS translocation variant 1 Human genes 0.000 claims 3
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 3
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 claims 3
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 3
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 claims 3
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 3
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims 3
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims 3
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 claims 3
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 3
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 3
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 3
- 102100035251 Protein C-ets-1 Human genes 0.000 claims 3
- 102100021890 Protein C-ets-2 Human genes 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000005945 translocation Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| US61/895,308 | 2013-10-24 | ||
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534084A JP2016534084A (ja) | 2016-11-04 |
| JP2016534084A5 true JP2016534084A5 (en:Method) | 2017-11-16 |
| JP6389884B2 JP6389884B2 (ja) | 2018-09-12 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526034A Active JP6389884B2 (ja) | 2013-10-24 | 2014-10-20 | 癌を治療するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (en:Method) |
| EP (1) | EP3060207A4 (en:Method) |
| JP (1) | JP6389884B2 (en:Method) |
| KR (1) | KR20160065986A (en:Method) |
| CN (1) | CN105848654B (en:Method) |
| AU (1) | AU2014340398A1 (en:Method) |
| CA (1) | CA2927148A1 (en:Method) |
| IL (1) | IL245281A0 (en:Method) |
| MX (1) | MX2016004678A (en:Method) |
| RU (1) | RU2016114498A (en:Method) |
| WO (1) | WO2015061229A1 (en:Method) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| PT2725028T (pt) | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
| IN2014DN09228A (en:Method) | 2012-04-12 | 2015-07-10 | Univ Georgetown | |
| AU2014340398A1 (en) * | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
| WO2016057698A1 (en) | 2014-10-09 | 2016-04-14 | Tokalas, Inc. | Indolinone compounds and uses thereof |
| ES2941630T3 (es) | 2014-11-16 | 2023-05-24 | Array Biopharma Inc | Forma cristalina de sulfato de hidrógeno de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN109219594B (zh) | 2016-03-31 | 2022-10-11 | 英克特诺治疗公司 | 吲哚啉类似物及其用途 |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| PE20190437A1 (es) | 2016-05-18 | 2019-03-27 | Loxo Oncology Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| KR102282794B1 (ko) | 2016-07-29 | 2021-07-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN110431241B (zh) * | 2017-02-28 | 2024-04-19 | 梅约医学教育与研究基金会 | 检测前列腺癌 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| WO2026009227A1 (en) | 2024-07-04 | 2026-01-08 | Yeda Research And Development Co. Ltd. | Compositions for downregulating zeb2 in macrophages and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
| AU1648600A (en) * | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| WO2006073458A2 (en) | 2004-04-30 | 2006-07-13 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| AU2007341977B2 (en) * | 2006-12-29 | 2013-05-23 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| WO2008130669A1 (en) | 2007-04-20 | 2008-10-30 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
| US20130259927A1 (en) * | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
| IN2014DN09228A (en:Method) | 2012-04-12 | 2015-07-10 | Univ Georgetown | |
| AU2014340398A1 (en) * | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
-
2014
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534084A5 (en:Method) | ||
| ES2690341T3 (es) | Derivados de 2-amino-5-trifluorometil-pirimidina y su uso como inhibidores de la quinasa PTK2 | |
| JP2016503797A5 (en:Method) | ||
| JP2015143283A5 (en:Method) | ||
| JP2015511638A5 (en:Method) | ||
| JP2017538689A5 (en:Method) | ||
| JP2019513770A5 (en:Method) | ||
| IL278297B2 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| JP2016526540A5 (en:Method) | ||
| JP2017527532A5 (en:Method) | ||
| JP2017511360A5 (en:Method) | ||
| JP2019512535A5 (en:Method) | ||
| JP2017531648A5 (en:Method) | ||
| JP2015532295A5 (en:Method) | ||
| IL273177B2 (en) | Fluorophenyl beta-hydroxyethylamines and their uses in the treatment of hyperglycemia | |
| JP2017510610A5 (en:Method) | ||
| JP2014530852A5 (en:Method) | ||
| JP2020506205A5 (en:Method) | ||
| JP2016505637A5 (en:Method) | ||
| JP2017533930A5 (en:Method) | ||
| JP2016510326A5 (en:Method) | ||
| RU2019142472A (ru) | Глюкуронидные пролекарства ингибиторов янус-киназы | |
| JP2021512055A5 (en:Method) | ||
| JP2016531871A5 (en:Method) | ||
| JP2016525104A5 (en:Method) |